drugset / Trial / NCT06114225

Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial

NCT06114225

Phase 2 Recruiting 43 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of pre-operative concurrent Stereotactic Body Radiotherapy (SBRT) and and programmed cell death protein-1 (PD-1) blockade immunotherapy followed by surgical metastasectomy for resectable metastatic osteosarcoma.

Timeline

Start
2023-06-01
Primary completion
2026-09-15
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule
Subject Penpulimab Monoclonal antibody

Indications